Biblio
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811-822.
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023.
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun. 2023;14(1):5335.